Gilead Sciences's basic earnings per share (Basic EPS) for the
three
months ended in Dec. 2023 was $1.15.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $4.55.
Gilead Sciences's EPS (Diluted) for the
three
months ended in Dec. 2023 was $1.14.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $4.50.
Gilead Sciences's EPS without NRI for the
three
months ended in Dec. 2023 was $1.72.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was 5.95.
During the past 12 months, Gilead Sciences's average EPS without NRIGrowth Rate was 13.80% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 24.50% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 4.80% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 1.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Gilead Sciences's highest 3-Year average EPS without NRI Growth Rate was 120.20% per year. The lowest was -50.90% per year. And the median was 4.90% per year.
Gilead Sciences EPS (Basic) Historical Data
The historical data trend for Gilead Sciences's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Gilead Sciences Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EPS (Basic)
4.24
0.10
4.96
3.66
4.54
Gilead Sciences Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EPS (Basic)
1.31
0.81
0.84
1.75
1.15
Gilead Sciences EPS (Basic) Calculation
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Gilead Sciences's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Gilead Sciences EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Gilead Sciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Gilead Sciences (Gilead Sciences) Business Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GILD has been successfully added to your 